Ranolazine has which characteristics in angina treatment?

Ranolazine has which characteristics in angina treatment?

• A. Reduces blood pressure and heart rate
• B. No CV benefit beyond limiting angina; no effect on blood pressure or heart rate; dizziness and QT prolongation as adverse effects
• C. Improves mortality
• D. First-line agent

Answer: (B)

Ranolazine works as an antianginal that relieves symptoms without changing blood pressure or heart rate, and it has not shown a mortality benefit. It acts by blocking the late sodium current in heart muscle, which reduces calcium overload during ischemia, lowers diastolic wall tension, and improves the heart’s efficiency in using oxygen. Because its effect is hemodynamically neutral, it doesn’t lower blood pressure or heart rate, and it isn’t proven to improve survival in stable angina, so it isn’t a first-line or mortality-advancing option. It’s typically added when standard therapies don’t fully control symptoms. The drug’s notable adverse effects include dizziness and QT interval prolongation, which can limit use or require caution with other QT-prolonging drugs or electrolyte disturbances.

Ranolazine works as an antianginal that relieves symptoms without changing blood pressure or heart rate, and it has not shown a mortality benefit. It acts by blocking the late sodium current in heart muscle, which reduces calcium overload during ischemia, lowers diastolic wall tension, and improves the heart’s efficiency in using oxygen. Because its effect is hemodynamically neutral, it doesn’t lower blood pressure or heart rate, and it isn’t proven to improve survival in stable angina, so it isn’t a first-line or mortality-advancing option. It’s typically added when standard therapies don’t fully control symptoms. The drug’s notable adverse effects include dizziness and QT interval prolongation, which can limit use or require caution with other QT-prolonging drugs or electrolyte disturbances.